Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: The LANDSCAPE trial

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 2999-3004

  Pierga, J Y ^a   Bidard, F C ^a   Cropet, C ^b   Tresca, P ^a   Dalenc, F ^c   Romieu, G ^d   Campone, M ^e   Aït Oukhatar, C Mahier ^f   Rhun, E Le ^g   Goncalves A ^h   Leheurteur, M ⁱ   Domont J ^j   Gutierrez, M ^k   Cure H ^l   Ferrero, J M ^m   Labbe Devilliers, C ^e   Bachelot, T ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE LÉON BÉRARD   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE VAL D AURELLE   (France)

^e Cancérologie de l'Ouest Institute   (France)

^f Unicancer RandD   (France)

^g CENTRE OSCAR LAMBRET   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ CENTRE HENRI BECQUEREL   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k Institut Curie Hôpital René Huguenin   (United States)

^l INSTITUT JEAN GODINOT   (France)

^m CENTRE ANTOINE LACASSAGNE   (France)

more..

Author keywords

Brain metastasis; Breast cancer; Capecitabine; Circulating tumor cells; HER2; Lapatinib

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN CELL; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME;

BRAIN METASTASIS; BREAST CANCER; CAPECITABINE; CIRCULATING TUMOR CELLS; HER2; LAPATINIB;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84888809627     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt348     Document Type: Article

References (21)

1. Pierga JY, Hajage D, Bachelot T et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-624.
2. Giordano A, Egleston BL, Hajage D et al. Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clin Cancer Res 2013; 19: 1596-1602.
3. Bidard FC, Fehm T, Ignatiadis M et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev 2013; 32: 179-188.
4. Bidard FC, Hajage D, Bachelot T et al. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer:a prospective observational study. Breast Cancer Res 2012; 14: R29.
5. Stemmler HJ, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008; 13: 739-750.
6. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009; 27:5278-5286.
7. Stemmler HJ, Schmitt M, Willems A et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18: 23-28.
8. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
9. Bartsch R, BerghoffA, Pluschnig U et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br J Cancer 2012; 106: 25-31.
10. Lin NU, Dieras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 15: 1452-1459.
11. Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14: 64-71.
12. Zhang L, Riethdorf S, Wu G et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012; 18: 5701-5710.
13. Giordano A, Giuliano M, De Laurentiis M et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012; 23:1144-1150.
14. Wallwiener M, Hartkopf AD, Baccelli I et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013; 137: 503-510.
15. Liu MC, Shields PG, Warren RD et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27: 5153-5159.
16. Nole F, Munzone E, Zorzino L et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-897.
17. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011; 11: 352-363.
18. Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 2011; 8: 369-377.
19. Taskar KS, Rudraraju V, Mittapalli RK et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res 2012; 29: 770-781.
20. Ligthart ST, Bidard FC, Decraene C et al. Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol 2013; 24:1231-1238.
21. Fehm T, Muller V, Aktas B et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 2010; 124: 403-412.